FourThought Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

FourThought Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$554K	Buy	804 +47	+6%	+$29.6K	0.08%	158
2022 Q2	$447K	Sell	757 -82	-10%	-$53.3K	0.07%	195
2022 Q1	$582K	Sell	839 -213	-20%	-$135K	0.07%	175
2021 Q4	$664K	Sell	1,052 -301	-22%	-$185K	0.08%	161
2021 Q3	$818K	Sell	1,353 -354	-21%	-$220K	0.11%	141
2021 Q2	$953K	Sell	1,707 -2,361	-58%	-$1.2M	0.13%	140
2021 Q1	$1.92M	Buy	4,068 +484	+14%	+$236K	0.28%	70
2020 Q4	$1.73M	Buy	+3,584	New	+$1.93M	0.28%	69

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FourThought Financial's REGN Position: Q3 2022 in Review

FourThought Financial increased its Regeneron Pharmaceuticals (REGN) stake by 6.2% in Q3 2022, buying an estimated $29.6K and bringing the position to 804 shares worth $554K. The position accounts for 0.08% of the portfolio, ranked #158.

FourThought Financial first reported a position in REGN in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.92M in Q1 2021. 1,081 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

FourThought Financial held 804 shares of Regeneron Pharmaceuticals worth $554K as of Q3 2022.
FourThought Financial bought 47 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $29.6K.
Regeneron Pharmaceuticals made up 0.08% of FourThought Financial's portfolio in Q3 2022, its #158 holding.
FourThought Financial first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Regeneron Pharmaceuticals position peaked at $1.92M in Q1 2021.
1,081 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.